Citigroup Begins Coverage on Telix Pharmaceuticals (NASDAQ:TLX)

Key Points

• Citigroup has initiated coverage on Telix Pharmaceuticals, assigning a "buy" rating with a price target of $22.00, indicating a potential upside of 134.54% from its current trading price of $9.38.
• Other analysts have similarly rated Telix Pharmaceuticals positively, with a consensus rating of "Moderate Buy" and an average price target of $21.50.
• Institutional investors have recently made significant investments in Telix Pharmaceuticals, with several firms purchasing new stakes, including ABC Arbitrage SA and Russell Investments Group Ltd.

Equities research analysts at Citigroup started coverage on shares of Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) in a research report issued on Thursday, MarketBeat.com reports. The brokerage set a "buy" rating and a $22.00 price target on the stock. Citigroup's price objective would suggest a potential upside of 120.44% from the company's previous close.

A number of other research firms also recently weighed in on TLX. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Wedbush restated an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. JPMorgan Chase & Co. restated a "neutral" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Finally, HC Wainwright reduced their price objective on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, September 10th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $21.50.

Telix Pharmaceuticals Price Performance

Shares of TLX stock traded up $0.82 on Thursday, hitting $9.98. The company's stock had a trading volume of 544,233 shares, compared to its average volume of 248,311. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. Telix Pharmaceuticals has a fifty-two week low of $8.93 and a fifty-two week high of $30.36. The stock's 50 day moving average is $11.88 and its 200-day moving average is $15.12.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of TLX. Private Advisor Group LLC purchased a new stake in shares of Telix Pharmaceuticals in the first quarter worth about $170,000. ABC Arbitrage SA bought a new position in shares of Telix Pharmaceuticals in the first quarter worth approximately $451,000. Blair William & Co. IL bought a new position in shares of Telix Pharmaceuticals in the second quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Telix Pharmaceuticals in the second quarter worth approximately $297,000. Finally, Pier Capital LLC bought a new position in shares of Telix Pharmaceuticals in the second quarter worth approximately $3,037,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.